OncoGenex initiates panreatic cancer trial OncoGenex (OGXI) initiates a Phase 2 study of an apatorsen/ Abraxane/ gemcitabine combo in patients with previously untreated metastatic pancreatic cancer.Primary endpoint is overall survival.Also evaluated: Progression-free survival, tumor response rates, safety, tolerability, and the effect of therapy on heat shock protein 27 levels
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.